Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes
Open Access
- 1 December 2006
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 116 (12) , 3171-3182
- https://doi.org/10.1172/jci29401
Abstract
Anaplastic large cell lymphomas (ALCLs) represent a subset of lymphomas in which the anaplastic lymphoma kinase (ALK) gene is frequently fused to the nucleophosmin (NPM) gene. We previously demonstrated that the constitutive phosphorylation of ALK chimeric proteins is sufficient to induce cellular transformation in vitro and in vivo and that ALK activity is strictly required for the survival of ALK-positive ALCL cells. To elucidate the signaling pathways required for ALK-mediated transformation and tumor maintenance, we analyzed the transcriptomes of multiple ALK-positive ALCL cell lines, abrogating their ALK-mediated signaling by inducible ALK RNA interference (RNAi) or with potent and cell-permeable ALK inhibitors. Transcripts derived from the gene expression profiling (GEP) analysis uncovered a reproducible signature, which included a novel group of ALK-regulated genes. Functional RNAi screening on a set of these ALK transcriptional targets revealed that the transcription factor C/EBPβ and the antiapoptotic protein BCL2A1 are absolutely necessary to induce cell transformation and/or to sustain the growth and survival of ALK-positive ALCL cells. Thus, we proved that an experimentally controlled and functionally validated GEP analysis represents a powerful tool to identify novel pathogenetic networks and validate biologically suitable target genes for therapeutic interventions.Keywords
This publication has 52 references indexed in Scilit:
- NPM-ALK–dependent expression of the transcription factor CCAAT/enhancer binding protein β in ALK-positive anaplastic large cell lymphomaBlood, 2006
- A loss-of-function RNA interference screen for molecular targets in cancerNature, 2006
- Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cellsBlood, 2006
- A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and anaplastic large cell lymphomasBlood, 2005
- A Genetic Screen for Candidate Tumor Suppressors Identifies RESTCell, 2005
- High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphomaJournal of Clinical Pathology, 2005
- Expression profiling reveals off-target gene regulation by RNAiNature Biotechnology, 2003
- CCAAT/enhancer-binding proteins: structure, function and regulationBiochemical Journal, 2002
- CCAAT enhancer- binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy.Journal of Clinical Investigation, 1998
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's LymphomaScience, 1994